Curis (CRIS) Misses Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Curis (CRIS) Misses Q3 EPS by 11c

Curis Reports Third Quarter 2016 Financial Results

November 3, 2016 7:00 AM EDT

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the third quarter ended September 30, 2016.

"We are pleased with our progress this quarter, and remain focused on patient enrollment within our two clinical programs. CA-170s Phase 1 trial is progressing rapidly through the dose escalation stage with no limiting adverse safety effects, said Ali Fattaey, Ph.D., Curis's CEO. Additionally, we continue to... More